Basic Information
| LncRNA/CircRNA Name | ZEB2-AS1 |
| Synonyms | NA |
| Region | GRCh38_2:144518097-144521477 |
| Ensemble | ENSG00000238057 |
| Refseq | NR_040248 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | Acute myeloid leukemia |
| ICD-0-3 | NA |
| Methods | qRT-PCR , RNAi etc. |
| Sample | cell lines(AP1060, NB4 and FKH-1 ),hematopoietic malignancies bone marrow specimens,normal eligible bone marrow specimens |
| Expression Pattern | up-regulated |
| Function Description | The results revealed that the expression of ZEB2-AS1 lncRNA was notably high and closely associated with adverse clinical outcomes in AML cases compared with the non-malignant cases, based on either modified Medical Research Council or European Leukemia Net risk stratification systems.Univariate analyses indicated that patients with a higher expression of ZEB2-AS1 lncRNA had significantly shorter overall survival(OS)and disease-free survival (DFS) rates (P=0.039) compared with patients with a lower expression of ZEB2-AS1 lncRNA.Furthermore, the knockdown of ZEB2-AS1 lncRNA effectively inhibited AML cell invasion and migration, which was closely associated with the downregulation of ZEB2 and upregulation of E-cadherin expression. |
| Pubmed ID | 31186703 |
| Year | 2019 |
| Title | Overexpression of ZEB2-AS1 lncRNA is associated with poor clinical outcomes in acute myeloid leukemia |
External Links
| Links for ZEB2-AS1 | GenBank HGNC NONCODE |
| Links for Acute myeloid leukemia | OMIM COSMIC |